Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advertisement
Amanda Nizam, MDAdvanced Urothelial Carcinoma | November 20, 2023
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
View More
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Peter O'Donnell, MDRoundtable | November 13, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Evan Yu, MDAdvanced Urothelial Carcinoma | November 2, 2023
Dr. Evan Yu opines on whether the EV-302 and CheckMate 901 data are practice-changing and when to recommend each combo.
Akhil Abraham Saji, MDAdvanced Urothelial Carcinoma | November 1, 2023
This is the first trial that has shown an OS benefit improvement over chemo in the 1L mUC setting, a landmark achievement.
Zachary BessetteAdvanced Urothelial Carcinoma | November 1, 2023
Lenvatinib plus pembrolizumab versus pembrolizumab alone as a first-line therapy for patients with advanced UC.
Emily MenendezAdvanced Urothelial Carcinoma | October 27, 2023
Erdafitinib was found to significantly improve OS and boost benefit over chemotherapy in patients with FGFRalt advanced/mUC.
Brad McGregor, MDESMO 2023 | October 25, 2023
Drs. McGregor, Sonpavde highlight the Double Antibody Drug conjugate trial, updates from THOR, and other studies.
Brad McGregor, MDESMO 2023 | October 25, 2023
Drs. McGregor, Sonpavde share how the data compare across CheckMate 901 and EV-302, as well as considerations for physicians.
Emily MenendezESMO 2023 | October 24, 2023
Paclitaxel administered with tremelimumab provided encouraging antitumor activity with a manageable safety profile.
Zachary BessetteESMO 2023 | October 23, 2023
The practice-changing results were presented at ESMO 2023.
Zachary BessetteESMO 2023 | October 23, 2023
Nivolumab plus gemcitabine-cisplatin demonstrated meaningful improvements in OS and PFS as first-line treatment of mUC.
Emily MenendezESMO 2023 | October 18, 2023
The combination of sacituzumab govitecan plus enfortumab vedotin was found to be safe, and provides a high ORR.
Advertisement
Advertisement
Advertisement